Clinical Trial: Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Study of a Short Course of Neoadjuvant Gleevec (Imatinib Mesylate) in Dermatofibrosarcoma Protuberans

Brief Summary: The purpose of this study is to examine the effect of imatinib on dermatofibrosarcoma protuberan tumors.

Detailed Summary:
Sponsor: Sarcoma Alliance for Research through Collaboration

Current Primary Outcome: To Collect Matched Tumor Tissue of Trial Participants With Dermatofibrosarcoma Protuberans Before and After Treatment With Imatinib for Future Use in cDNA Microarray and Tissue Array Studies. [ Time Frame: Prior to and after 2-weeks of imatinib therapy ]

To obtain matched tumor tissue samples of trial participants dermatofibrosarcoma protuberans (DFSP)for the purpose of determining whether imatinib mesylate affects autocrine/paracrine stimulated signal transduction through the platelet-derived growth factor receptor pathway in DFSP by comparing the level of phosphorylated platelet-derived growth factor receptor beta (PDGFRB) in DFSP after up to 2 weeks of treatment with imatinib to the level of phosphorylated PDGFRB pre-treatment.


Original Primary Outcome: Comparison of PDGFRB in tumor sample obtained prior to imatinib with sample obtained following 2 weeks of imatinib therapy

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Sarcoma Alliance for Research through Collaboration

Dates:
Date Received: October 20, 2005
Date Started: May 2006
Date Completion:
Last Updated: February 14, 2012
Last Verified: February 2012